Compare Canadian National Railway Co. (CNI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian National Railway Co. vs Viatris Inc — how do they compare? Canadian National Railway Co. trades at $126.48 (market cap $76.28B), while Viatris Inc trades at $16.2 (market cap $18.69B). The key difference: Canadian National Railway Co. is far larger — about 4.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| CNI | VTRS | |
|---|---|---|
Market Cap | $76.28B | $18.69B |
Sector | Industrials | Health |
52-Week High | $130.58 | $17.86 |
52-Week Low | $90.91 | $9.49 |
Enterprise Value | $92.31B | $30.80B |
Dividend Yield | 2.06% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CNI trades at $126.32, up 0.94% today, with a neutral technical signal and bullish moving average trend. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.50 versus $1.39 expected, and raised full-year guidance. Key financials show a P/E of 22.62, net income margin of 26.92%, and ROE of 22.02%, supported by record grain movements in the 2025-26 crop year.
Outlook is positive due to operational excellence and volume growth, but valuation appears stretched with a consensus price target of $152.38. Risks include competitive pressures and macroeconomic volatility, while institutional sentiment leans neutral with 60.79% hold ratings.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
